Zhejiang Daoming Pharmaceutical Technology

Zhejiang Daoming Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Hangzhou, China, dedicated to the discovery and development of innovative small molecule drugs. The company focuses on therapeutic areas with significant unmet needs, particularly immunology, oncology, and metabolic diseases. Its lead program, DM-001, is a highly selective Janus kinase 3 (JAK3) inhibitor currently in Phase 2 clinical trials for the treatment of alopecia areata and other autoimmune conditions. Daoming Pharmaceutical utilizes a proprietary drug discovery platform to design molecules with improved selectivity and safety profiles compared to existing therapies. The company is led by a team of experienced scientists with backgrounds in global pharmaceutical R&D and medicinal chemistry.